SciQuus Oncology initiates operations
January 1, 2014
SciQuus Oncology is a specialty contract research organization focused on oncology drug development. SciQuus Oncology was initially spun out from the clinical oncology research group at Proacta Incorporated. This group has experience spanning 30 years in the design and execution of oncology drug development programs for small molecules, biologics and anti-cancer vaccines with several of the programs progressing from the initial studies required to obtain an IND to phase III registration studies. The group brings with it an established network of contacts within the oncology and regulatory communities. SciQuus Oncology will focus on working with pharmaceutical and biotechnology companies in the conduct of their preclinical and clinical development programs. In addition, all current and future trials conducted by Proacta will be conducted under contract by SciQuus Oncology.
About SciQuus Oncology Incorporated
SciQuus Oncology is focused on providing clinical trial and drug development resources to the pharmaceutical and biopharmaceutical industries. SciQuus Oncology was formed and incorporated in late 2013 as a spin out from the clinical research division at Proacta Inc.
About Proacta Incorporated
Proacta is a San Diego based biotechnology company dedicated to the development and commercialization of hypoxia-activated oncology drugs. Proacta is currently conducting a phase I/II study of PR610, a hypoxia activated multikinase inhibitor, targeting patients with T790M-positive non-small cell lung cancer. In addition, Proacta was formed based on hypoxia-activated prodrugs licensed from the University of Auckland in New Zealand. For more information on Proacta, visit the Proacta web site at www.proacta.com.